Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • Reproductive risk factors associated with breast cancer in young women by molecular subtype.
    • Ruddy KJ, Vierkant RA, Jahan N, Higgins A, Partridge A, Larson N, Radisky DC, Couch F, Olson J, Sherman ME.
    • Breast. 2022 Nov 9:S0960-9776(22)00187-4. doi: 10.1016/j.breast.2022.11.004. Epub ahead of print.

    • Using a machine learning algorithm to predict outcome of primary cytoreductive surgery in advanced ovarian cancer.
    • Piedimonte S, Erdman L, So D, Bernardini MQ, Ferguson SE, Laframboise S, Bouchard Fortier G, Cybulska P, May T, Hogen L.
    • J Surg Oncol. 2022 Nov 9. doi: 10.1002/jso.27137. Epub ahead of print.

    • Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
    • Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, Alarcón J, Calzas J, Gaba L, Fuentes J, Santaballa A, Salvador C, Manso L, Herrero A, Taus Á, Márquez R, Madani J, Merino M, Marquina G, Casado V, Constenla M, Gutiérrez M, Dosil A, González-Martín A.
    • BMC Cancer. 2022 Nov 8;22(1):1150. doi: 10.1186/s12885-022-10191-5.

    • NBN pathogenic germline variants are associated with pan-cancer susceptibility and in vitro DNA damage response defects.
    • Belhadj S, Khurram A, Bandlamudi C, Palou-Márquez G, Ravichandran V, Steinsnyder Z, Wildman T, Catchings A, Kemel Y, Mukherjee S, Fesko B, Arora K, Mehine M, Dandiker S, Izhar A, Petrini J, Domchek S, Nathanson KL, Brower J, Couch F, Stadler Z, Robson M, Walsh M, Vijai J, Berger M, Supek F, Karam R, Topka S, Offit K.
    • Clin Cancer Res. 2022 Nov 8:CCR-22-1703. doi: 10.1158/1078-0432.CCR-22-1703. Epub ahead of print.

    • Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    • Washington CR, Moore KN.
    • Curr Oncol Rep. 2022 Nov 8. doi: 10.1007/s11912-022-01337-6. Epub ahead of print.
    • Review

    • Study: More is not better: PARP dose can be safely reduced for people with ovarian cancer.
    • [No author given]
    • FORCE. XRAY. 2022 Nov 8.

    Related:

    •• Original research:

    The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

    • Tests to Guide PARP Inhibitors Emerge as New Focus for Public-Private Harmonization Effort.
    • Ashford K.
    • Precision Oncology News. 2022 Nov 8.
    • News

    • A genome-wide association study of mammographic texture variation.
    • Liu Y, Chen H, Heine J, Lindstrom S, Turman C, Warner ET, Winham SJ, Vachon CM, Tamimi RM, Kraft P, Jiang X.
    • Breast Cancer Res. 2022 Nov 7;24(1):76. doi: 10.1186/s13058-022-01570-8.

    • Germline Pathogenic Variants Associated with Ovarian Cancer: A Historical Overview.
    • Lund Johansen E, Fribert Thusgaard C, Thomassen M, Eriksen Boonen S, Jochumsen KM.
    • Gynecol Oncol Rep. 2022 Nov 8;101105. doi: 10.1016/j.gore.2022.101105.

    • LitAlert ~~ GeneLit.com

    • Implementation of multigene panel testing for breast and ovarian cancer in South Africa: a step towards excellence in Oncology for the public sector.
    • Van Der Merwe NC, Ntaita KS, Stofberg H, Combrink HM, Oosthuizen J, Kotze MJ.
    • Front Oncol. 2022 Nov 8;12:938561. doi: 10.3389/fonc.2022.938561.

    • Society of Gynecologic Oncology Journal Club: Controversial Conversations in Gynecologic Cancer - Navigating Maintenance Therapy for Homologous Recombinant Proficient Ovarian Cancer.
    • Goldsberry WN, Norquist BS, Rocconi RP, Modesitt SC, Urban RR.
    • Gynecol Oncol Rep. 2022 Nov 8;101103. doi: 10.1016/j.gore.2022.101103.

    • Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
    • Giuliani J, Mantoan B, Ferrario L, Candela MV, Aprile G.
    • J Oncol Pharm Pract. 2022 Nov 7:10781552221137705. doi: 10.1177/10781552221137705. Epub ahead of print.

    • Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.
    • Shah JB, Pueschl D, Wubbenhorst B, Fan M, Pluta J, D'Andrea K, Hubert AP, Shilan JS, Zhou W, Kraya AA, Llop Guevara A, Ruan C, Serra V, Balmaña J, Feldman M, Morin PJ, Nayak A, Maxwell KN, Domchek SM, Nathanson KL.
    • Nat Commun. 2022 Nov 7;13(1):6728. doi: 10.1038/s41467-022-34523-y.

    • Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.
    • Ren J, Quan X, Liu Y, Li J, Zhang X, Li Z, Zhang X.
    • Bioorg Med Chem Lett. 2022 Nov 4:129046. doi: 10.1016/j.bmcl.2022.129046. Epub ahead of print.

    • A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
    • Naiki T, Naiki-Ito A, Kawai T, Komatsu H, Nishikawa R, Gonda M, Aoki M, Sugiyama Y, Tasaki Y, Yasui T.
    • IJU Case Rep. 2022 Jun 29 [eCollection 2022 Nov];5(6):431-435. doi: 10.1002/iju5.12501.

    Related:

    •• Commentary:

    Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.

    •• Commentary:

    Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.

    • Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation.
    • Yabusaki R, Yoshimura K, Taku K, Suzuki M.
    • IJU Case Rep. 2022 Aug 12 [eCollection 2022 Nov];5(6):489-492. doi: 10.1002/iju5.12523.

    • LitAlert ~~ GeneLit.com

    • The prevalence of germline pathogenic variants in Estonian colorectal cancer patients: results from routine clinical setting 2016–2021.
    • Roht L, Tooming M, Rekker K, Roomere H, Toome K, Murumets Ü, Šamarina U, Õunap K, Kahre T.
    • Front Genet. 2022 Nov 8;12:1020543. doi: 10.3389/fgene.2022.1020543.

    • Society of Gynecologic Oncology Journal Club: Controversial Conversations in Gynecologic Cancer - Navigating Maintenance Therapy for Homologous Recombinant Proficient Ovarian Cancer.
    • Goldsberry WN, Norquist BS, Rocconi RP, Modesitt SC, Urban RR.
    • Gynecol Oncol Rep. 2022 Nov 8;101103. doi: 10.1016/j.gore.2022.101103.

    • Germline Pathogenic Variants Associated with Ovarian Cancer: A Historical Overview.
    • Lund Johansen E, Fribert Thusgaard C, Thomassen M, Eriksen Boonen S, Jochumsen KM.
    • Gynecol Oncol Rep. 2022 Nov 8;101105. doi: 10.1016/j.gore.2022.101105.

    • A genome-wide association study of mammographic texture variation.
    • Liu Y, Chen H, Heine J, Lindstrom S, Turman C, Warner ET, Winham SJ, Vachon CM, Tamimi RM, Kraft P, Jiang X.
    • Breast Cancer Res. 2022 Nov 7;24(1):76. doi: 10.1186/s13058-022-01570-8.

    • Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers.
    • Mori T, Okamoto Y, Mu A, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura S, Matsuo K, Takata M.
    • Cancer Med. 2022 Nov 7. doi: 10.1002/cam4.5430. Epub ahead of print.

    • Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
    • Giuliani J, Mantoan B, Ferrario L, Candela MV, Aprile G.
    • J Oncol Pharm Pract. 2022 Nov 7:10781552221137705. doi: 10.1177/10781552221137705. Epub ahead of print.

    • Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.
    • Shah JB, Pueschl D, Wubbenhorst B, Fan M, Pluta J, D'Andrea K, Hubert AP, Shilan JS, Zhou W, Kraya AA, Llop Guevara A, Ruan C, Serra V, Balmaña J, Feldman M, Morin PJ, Nayak A, Maxwell KN, Domchek SM, Nathanson KL.
    • Nat Commun. 2022 Nov 7;13(1):6728. doi: 10.1038/s41467-022-34523-y.

    • A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
    • Naiki T, Naiki-Ito A, Kawai T, Komatsu H, Nishikawa R, Gonda M, Aoki M, Sugiyama Y, Tasaki Y, Yasui T.
    • IJU Case Rep. 2022 Jun 29 [eCollection 2022 Nov];5(6):431-435. doi: 10.1002/iju5.12501.

    Related:

    •• Commentary:

    Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.

    •• Commentary:

    Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.

    • Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation.
    • Yabusaki R, Yoshimura K, Taku K, Suzuki M.
    • IJU Case Rep. 2022 Aug 12 [eCollection 2022 Nov];5(6):489-492. doi: 10.1002/iju5.12523.

    • LitAlert ~~ GeneLit.com

    • The prevalence of germline pathogenic variants in Estonian colorectal cancer patients: results from routine clinical setting 2016–2021.
    • Roht L, Tooming M, Rekker K, Roomere H, Toome K, Murumets Ü, Šamarina U, Õunap K, Kahre T.
    • Front Genet. 2022 Nov 8;12:1020543. doi: 10.3389/fgene.2022.1020543.

    • Implementation of multigene panel testing for breast and ovarian cancer in South Africa: a step towards excellence in Oncology for the public sector.
    • Van Der Merwe NC, Ntaita KS, Stofberg H, Combrink HM, Oosthuizen J, Kotze MJ.
    • Front Oncol. 2022 Nov 8;12:938561. doi: 10.3389/fonc.2022.938561.

    • Germline Pathogenic Variants Associated with Ovarian Cancer: A Historical Overview.
    • Lund Johansen E, Fribert Thusgaard C, Thomassen M, Eriksen Boonen S, Jochumsen KM.
    • Gynecol Oncol Rep. 2022 Nov 8;101105. doi: 10.1016/j.gore.2022.101105.

    • Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers.
    • Mori T, Okamoto Y, Mu A, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura S, Matsuo K, Takata M.
    • Cancer Med. 2022 Nov 7. doi: 10.1002/cam4.5430. Epub ahead of print.

    • A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
    • Naiki T, Naiki-Ito A, Kawai T, Komatsu H, Nishikawa R, Gonda M, Aoki M, Sugiyama Y, Tasaki Y, Yasui T.
    • IJU Case Rep. 2022 Jun 29 [eCollection 2022 Nov];5(6):431-435. doi: 10.1002/iju5.12501.

    Related:

    •• Commentary:

    Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.

    •• Commentary:

    Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.

    • Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation.
    • Yabusaki R, Yoshimura K, Taku K, Suzuki M.
    • IJU Case Rep. 2022 Aug 12 [eCollection 2022 Nov];5(6):489-492. doi: 10.1002/iju5.12523.

    • LitAlert ~~ GeneLit.com

    • Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51.
    • Heijink AM, Stok C, Porubsky D, Manolika EM, de Kanter JK, Kok YP, Everts M, de Boer HR, Audrey A, Bakker FJ, Wierenga E, Tijsterman M, Guryev V, Spierings DCJ, Knipscheer P, van Boxtel R, Ray Chaudhuri A, Lansdorp PM, van Vugt MATM.
    • Nat Commun. 2022 Nov 7;13(1):6722. doi: 10.1038/s41467-022-34519-8.

    • Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.
    • Ren J, Quan X, Liu Y, Li J, Zhang X, Li Z, Zhang X.
    • Bioorg Med Chem Lett. 2022 Nov 4:129046. doi: 10.1016/j.bmcl.2022.129046. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
    • Naiki T, Naiki-Ito A, Kawai T, Komatsu H, Nishikawa R, Gonda M, Aoki M, Sugiyama Y, Tasaki Y, Yasui T.
    • IJU Case Rep. 2022 Jun 29 [eCollection 2022 Nov];5(6):431-435. doi: 10.1002/iju5.12501.

    Related:

    •• Commentary:

    Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.

    •• Commentary:

    Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.

    • Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation.
    • Yabusaki R, Yoshimura K, Taku K, Suzuki M.
    • IJU Case Rep. 2022 Aug 12 [eCollection 2022 Nov];5(6):489-492. doi: 10.1002/iju5.12523.

    • LitAlert ~~ GeneLit.com

    • Implementation of multigene panel testing for breast and ovarian cancer in South Africa: a step towards excellence in Oncology for the public sector.
    • Van Der Merwe NC, Ntaita KS, Stofberg H, Combrink HM, Oosthuizen J, Kotze MJ.
    • Front Oncol. 2022 Nov 8;12:938561. doi: 10.3389/fonc.2022.938561.

    • Germline Pathogenic Variants Associated with Ovarian Cancer: A Historical Overview.
    • Lund Johansen E, Fribert Thusgaard C, Thomassen M, Eriksen Boonen S, Jochumsen KM.
    • Gynecol Oncol Rep. 2022 Nov 8;101105. doi: 10.1016/j.gore.2022.101105.

    • LitAlert ~~ GeneLit.com

    • The prevalence of germline pathogenic variants in Estonian colorectal cancer patients: results from routine clinical setting 2016–2021.
    • Roht L, Tooming M, Rekker K, Roomere H, Toome K, Murumets Ü, Šamarina U, Õunap K, Kahre T.
    • Front Genet. 2022 Nov 8;12:1020543. doi: 10.3389/fgene.2022.1020543.

    • Implementation of multigene panel testing for breast and ovarian cancer in South Africa: a step towards excellence in Oncology for the public sector.
    • Van Der Merwe NC, Ntaita KS, Stofberg H, Combrink HM, Oosthuizen J, Kotze MJ.
    • Front Oncol. 2022 Nov 8;12:938561. doi: 10.3389/fonc.2022.938561.

    • Society of Gynecologic Oncology Journal Club: Controversial Conversations in Gynecologic Cancer - Navigating Maintenance Therapy for Homologous Recombinant Proficient Ovarian Cancer.
    • Goldsberry WN, Norquist BS, Rocconi RP, Modesitt SC, Urban RR.
    • Gynecol Oncol Rep. 2022 Nov 8;101103. doi: 10.1016/j.gore.2022.101103.

    • Germline Pathogenic Variants Associated with Ovarian Cancer: A Historical Overview.
    • Lund Johansen E, Fribert Thusgaard C, Thomassen M, Eriksen Boonen S, Jochumsen KM.
    • Gynecol Oncol Rep. 2022 Nov 8;101105. doi: 10.1016/j.gore.2022.101105.

    • A genome-wide association study of mammographic texture variation.
    • Liu Y, Chen H, Heine J, Lindstrom S, Turman C, Warner ET, Winham SJ, Vachon CM, Tamimi RM, Kraft P, Jiang X.
    • Breast Cancer Res. 2022 Nov 7;24(1):76. doi: 10.1186/s13058-022-01570-8.

    • Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers.
    • Mori T, Okamoto Y, Mu A, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura S, Matsuo K, Takata M.
    • Cancer Med. 2022 Nov 7. doi: 10.1002/cam4.5430. Epub ahead of print.

    • Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
    • Giuliani J, Mantoan B, Ferrario L, Candela MV, Aprile G.
    • J Oncol Pharm Pract. 2022 Nov 7:10781552221137705. doi: 10.1177/10781552221137705. Epub ahead of print.

    • Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51.
    • Heijink AM, Stok C, Porubsky D, Manolika EM, de Kanter JK, Kok YP, Everts M, de Boer HR, Audrey A, Bakker FJ, Wierenga E, Tijsterman M, Guryev V, Spierings DCJ, Knipscheer P, van Boxtel R, Ray Chaudhuri A, Lansdorp PM, van Vugt MATM.
    • Nat Commun. 2022 Nov 7;13(1):6722. doi: 10.1038/s41467-022-34519-8.

    • Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.
    • Shah JB, Pueschl D, Wubbenhorst B, Fan M, Pluta J, D'Andrea K, Hubert AP, Shilan JS, Zhou W, Kraya AA, Llop Guevara A, Ruan C, Serra V, Balmaña J, Feldman M, Morin PJ, Nayak A, Maxwell KN, Domchek SM, Nathanson KL.
    • Nat Commun. 2022 Nov 7;13(1):6728. doi: 10.1038/s41467-022-34523-y.

    • A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
    • Naiki T, Naiki-Ito A, Kawai T, Komatsu H, Nishikawa R, Gonda M, Aoki M, Sugiyama Y, Tasaki Y, Yasui T.
    • IJU Case Rep. 2022 Jun 29 [eCollection 2022 Nov];5(6):431-435. doi: 10.1002/iju5.12501.

    Related:

    •• Commentary:

    Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.

    •• Commentary:

    Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.

    • Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation.
    • Yabusaki R, Yoshimura K, Taku K, Suzuki M.
    • IJU Case Rep. 2022 Aug 12 [eCollection 2022 Nov];5(6):489-492. doi: 10.1002/iju5.12523.